Ticho Barry sold $208K of STOK
Ticho Barry (CHIEF MEDICAL OFFICER) sold 7,176 shares of Stoke Therapeutics, Inc. (STOK) at an average of $29.04 ($28.95–$29.45, $0.21M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the Aug 3 open-market sale by the company’s Chief Medical Officer, totaling about $208k, executed under a 10b5-1 plan.
Market read
For STOK, this is primarily a sentiment datapoint rather than a catalyst for fundamentals.
What to watch
Traders may overreact to insider selling without considering that the filing does not provide new information about pipeline, trial results, or financing.
Background
The article is an SEC Form 4 insider transaction disclosure for Stoke Therapeutics, Inc. (STOK).
Ticker impact
Stoke Therapeutics disclosed via Form 4 that CMO Ticho Barry sold 7,176 shares in open-market transactions under a 10b5-1 plan.
Likely limited, short-lived impact; any move would be sentiment-driven rather than driven by new company fundamentals.
The filing is a primary-source Form 4 and includes trade size, dates, and 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single insider sale at one biotech.
None.
None.
Counterpoint
Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerStoke Therapeutics, Inc.
Biopharma company whose insider transaction was disclosed on Form 4.
- insiderTicho Barry
Chief Medical Officer who sold 7,176 shares across two trades on Aug 3 under a 10b5-1 plan.
